We have identified satraplatin as having a significant effect in haemato-oncology indications and are developing it as a precision platinum for orphan lymphomas.
We are scaling up the identification and development of clinical compounds using proprietary oncologist know-how by amplifying the process with AI and data mining to systematically pursue high-yield candidates for cancer indications of large unmet medical need.